Impact of Neoadjuvant Chemotherapy With or Without Zometa on Occult Micrometastases and Bone Density in Women With Locally Advanced Breast Cancer
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment
Evaluate the impact of Zometa (zoledronic acid) on the clearance of bone marrow micrometastases
Prior to therapy initiation, after completion of neoadjuvant chemotherapy, and 12-15 months from registration
No
Rebecca Aft, M.D., Ph.D.
Principal Investigator
Washington University School of Medicine
United States: Institutional Review Board
02-0788 / 201104272
NCT00242203
October 2002
May 2011
Name | Location |
---|---|
Washington University School of Medicine | Saint Louis, Missouri 63110 |